Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Front Pharmacol ; 11: 79, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32153402

RESUMEN

Doxorubicin (DOX) is an anticancer drug widely used in oncology. The main limitation to DOX treatments though is due to the cumulative dose that may lead to cardiotoxicity. Clinically, DOX-induced cardiomyopathy develops as a progressive heart failure consecutive to a progressive loss in cardiomyocytes due to cell necrosis and apoptosis induced by DOX. For many years, the cardiac oxidative stress caused by DOX was considered as its main toxic mechanism. Therefore, several clinical trials were carried out to assess the efficacy of various antioxidants as a cardioprotective strategy. Only dexrazoxane (DEX), did significantly reduce DOX cardiotoxicity. However, since other antioxidants used later on to counteract DOX cardiotoxicity were not as successful as DEX, DOX-induced oxidative stress and DEX antioxidant activity are not considered as the main feature anymore and this led the scientific world to suspect other involved mechanisms which are still unknown. The objective of the present work was to study from a metabolic point of view the side effects of DOX and the protective properties of DEX. In vitro 1H-NMR metabonomics was applied to the rat cardiomyoblastic H9C2 cell line. This strategy was used with the hope of unveiling possible new targets to cope with DOX cardiotoxicity. Another underlying goal was the validation of H9C2 in vitro model for metabolic investigations of DOX and DEX effects. For this purpose, several parameters, including oxidative stress, cell mortality, and apoptosis, were measured to assess the effects of DOX and DEX alone or in combination. The metabonomic study was carried out on cellular fluids collected after either 4 or 24 hours of DOX-exposure. Under such experimental conditions, both the major adverse effects reported in patients exposed to DOX and the protective effect of DEX were demonstrated in vitro, suggesting that the H9C2 in vitro model is relevant to investigate both DOX cardiotoxicity and putative cardioprotective strategies. In addition, the metabonomics findings highlighted several metabolic pathways involved in DOX cardiotoxicity and DEX cardioprotective effects as potential metabolic targets for cardioprotection: energy metabolism, redox balance, as well as phospholipids and proteins metabolism.

2.
Open Forum Infect Dis ; 3(3): ofw128, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27419189

RESUMEN

Background. Early diagnosis and treatment are crucial in invasive fungal diseases (IFD). Serum (1-3)-ß-d-glucan (BG) is believed to be an early IFD marker, but its diagnostic performance has been ambiguous, with insufficient data regarding sensitivity at the time of IFD diagnosis (TOD) and according to outcome. Whether its clinical utility is equivalent for all types of IFD remains unknown. Methods. We included 143 patients with proven or probable IFD (49 invasive candidiasis, 45 invasive aspergillosis [IA], and 49 rare IFD) and analyzed serum BG (Fungitell) at TOD and during treatment. Results. (1-3)-ß-d-glucan was undetectable at TOD in 36% and 48% of patients with candidemia and IA, respectively; there was no correlation between negative BG results at TOD and patients' characteristics, localization of infection, or prior antifungal use. Nevertheless, patients with candidemia due to Candida albicans were more likely to test positive for BG at TOD (odds ratio = 25.4, P = .01) than patients infected with other Candida species. In 70% of the patients with a follow-up, BG negativation occurred in >1 month for candidemia and >3 months for IA. A slower BG decrease in patients with candidemia was associated with deep-seated localizations (P = .04). Thirty-nine percent of patients with rare IFD had undetectable BG at TOD; nonetheless, all patients with chronic subcutaneous IFD tested positive at TOD. Conclusions. Undetectable serum BG does not rule out an early IFD, when the clinical suspicion is high. After IFD diagnostic, kinetics of serum BG are difficult to relate to clinical outcome.

3.
Biomed Mater Eng ; 16(4): 253-9, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16971743

RESUMEN

The bone samples used in clinical and experimental trials must be the less damaged as possible to avoid alterations of their properties. However, the mode of storage might possibly alter the bone properties, particularly microarchitecture and strength. The aim of our study was to analyze the effects of deep-freezing and alcohol conservation techniques on the densitometric, microarchitectural and biomechanical parameters of rat femurs. The left femurs were elongated in uniaxial tension up to breakdown in order to calculate biomechanical parameters. The densitometric and microarchitectural properties of right femurs were evaluated using dual-energy X-ray absorptiometry and microcomputed tomography, respectively. Results showed no significant difference in the parameters investigated between deep-freezing, alcohol storage and fresh femurs when comparing each parameter separately. Therefore, one month storage in alcohol or deep-freezing seemed to induce no harmful effect on densitometric, microarchitectural and biomechanical parameters of rat femurs.


Asunto(s)
Densidad Ósea/fisiología , Fémur/citología , Fémur/fisiología , Conservación de Tejido/métodos , Animales , Etanol , Congelación , Técnicas In Vitro , Masculino , Ratas , Ratas Wistar , Resistencia a la Tracción
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA